LONDON, March 16 (Reuters) - Adding GlaxoSmithKline Plc's (GSK.L: Quote, Profile , Research) top-selling drug Advair to Pfizer Inc's (PFE.N: Quote, Profile , Research) Spiriva does not reduce exacerbations in patients with COPD, or smoker's lung, according to new research.
